MEX3A is a diagnostic, independent prognostic biomarker and a promising therapeutic target in glioblastoma
Our findings highlight MEX3A as a novel diagnostic and prognostic biomarker and a promising therapeutic target for GB.
Authors
- Laura Di Magno (ORCID: https://orcid.org/0000-0001-9446-8752)
- Antonino Cucinotta (ORCID: https://orcid.org/0000-0002-3375-0209)
- Alessandro Frati (ORCID: https://orcid.org/0000-0001-8062-614X)
- Paola Infante (ORCID: https://orcid.org/0000-0003-0682-3916)
- Daniele Armocida (ORCID: https://orcid.org/0000-0001-6550-5534)
- Francesca Agnoli
- Pietro Familiari (ORCID: https://orcid.org/0000-0003-0513-2312)
- Luca D’Angelo (ORCID: https://orcid.org/0000-0001-9182-1928)
- Alessandra Serraino
- Lucia Di Marcotullio (ORCID: https://orcid.org/0000-0003-0274-7178)
- Francesca Bufalieri (ORCID: https://orcid.org/0000-0002-9571-318X)
- Gianluca Canettieri (ORCID: https://orcid.org/0000-0001-6694-2613)
- Antonio Santoro (ORCID: https://orcid.org/0000-0002-0798-6816)
- Ludovica Lospinoso Severini (ORCID: https://orcid.org/0000-0002-1032-5496)
- Manila Antonelli (ORCID: https://orcid.org/0000-0002-9535-931X)
- Gennaro Adabbo
Institutions
- Istituto Neurologico Mediterraneo (IT)
- Istituto Pasteur (IT)
- Sapienza University of Rome (IT)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-09-01
- DOI
- https://doi.org/10.3389/fonc.2025.1585592
- Primary Topic
- interferon and immune responses
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Fondazione Umberto Veronesi